Insulin is not a controlled substance. It does not appear on any of the five schedules of the Controlled Substances Act, and the Drug Enforcement Administration has no role in regulating it. Insulin is classified as a biological product regulated by the FDA under the Public Health Service Act.
Why Insulin Is Not Scheduled
The Controlled Substances Act uses eight factors to determine whether a drug should be scheduled, and the core question is whether the substance has potential for abuse. Drugs that qualify generally have central nervous system activity and produce euphoria, hallucinations, or other mood-altering effects. Scheduling also considers whether a drug creates psychological or physical dependence, meaning people develop impaired control over their use because of the rewarding sensations it produces.
Insulin doesn’t meet any of these criteria. It’s a hormone that regulates blood sugar. It doesn’t act on the brain’s reward system, doesn’t produce a high, and doesn’t create the kind of dependence that drives compulsive use. People with diabetes depend on insulin to survive, but that’s a physiological need, not the addictive dependence the scheduling system is designed to address.
Prescription vs. Over-the-Counter Insulin
Even though insulin isn’t a controlled substance, some forms do require a prescription. The distinction comes down to the type of insulin. Analog insulins, which are newer, modified versions designed for faster or longer action, require a prescription everywhere in the United States. These include the rapid-acting and long-acting formulations most commonly prescribed today.
Older human insulin formulations, specifically Regular (short-acting) and NPH (intermediate-acting), can be purchased without a prescription in the vast majority of states. Walmart, for example, sells these under its ReliOn brand over the counter. In a state-by-state breakdown, nearly every state allows you to buy Regular and NPH insulin without a prescription. Alaska is the notable exception, where prescriptions may be required, though even there reports are inconsistent.
Syringe access is a separate issue. Most states allow you to buy syringes without a prescription, but a handful, including Connecticut, Delaware, Maine, and New Jersey, do require one. Indiana and Maryland require you to sign a logbook when purchasing syringes. Florida prohibits providing syringes to minors without a prescription. New York leaves the decision to individual pharmacies and limits purchases to 10 syringes at a time without a prescription.
How Insulin Is Regulated Instead
Since March 2020, the FDA classifies insulin products as biologics under the Public Health Service Act. Before that, insulin was regulated as a drug under the Federal Food, Drug, and Cosmetic Act. The shift was designed to open the door for biosimilar insulin products, which could increase competition and lower prices. The FDA still oversees manufacturing standards, labeling, and approval for all insulin products, but none of this involves the DEA or controlled substance tracking.
This means pharmacies don’t need to store insulin in a locked cabinet, don’t need to file DEA reports when dispensing it, and don’t need to track it the way they would opioids or stimulants. For you as a patient, it means no special prescription pads, no refill limits tied to scheduling, and no legal complications for possessing it.
Traveling With Insulin
Because insulin is not a controlled substance, traveling with it is straightforward. The TSA allows insulin, syringes, insulin pumps, and glucose monitors in both carry-on and checked bags. You should let the screening officer know you’re carrying medically necessary supplies, especially if you have a pump or monitor attached to your body. The TSA’s general guidance is simple: declare it and expect a visual inspection.
For international travel or importing insulin, the FDA’s personal importation policy allows a supply of up to 90 days. You’ll need to provide either the name and address of a U.S.-licensed doctor responsible for your treatment or evidence that the medication continues a treatment started abroad. Foreign nationals visiting the U.S. can bring or have shipped a 90-day supply, with documentation like a passport copy, doctor’s letter, or prescription translated into English.
Insulin Misuse and Its Legal Status
Insulin does get misused in some contexts, particularly in bodybuilding, where some athletes inject short-acting insulin and consume sugary foods around workouts to promote muscle growth. This practice is genuinely dangerous. Improper use can cause severe hypoglycemia, which can lead to seizures, loss of consciousness, and death. Combining insulin with anabolic steroids and growth hormone, a pattern seen in recreational bodybuilders, raises the risk of heart attack, stroke, and long-term hormonal disruption.
Despite this misuse, insulin still doesn’t meet the criteria for scheduling. It doesn’t produce euphoria or psychological reward, and its misuse pattern is narrow compared to substances like opioids or stimulants. Interestingly, while the World Anti-Doping Agency bans insulin use in competition, current lab techniques cannot reliably detect exogenous insulin abuse, making it one of the few performance-enhancing substances that escapes standard testing.
Recent Changes to Insulin Affordability
While insulin’s legal classification hasn’t changed, its cost landscape has shifted significantly. The Inflation Reduction Act capped out-of-pocket insulin costs at $35 per monthly prescription for Medicare Part D enrollees starting January 1, 2023, with a similar cap for Medicare Part B taking effect July 1, 2023. These caps also eliminated deductibles for covered insulin products. An estimated 1.5 million Medicare beneficiaries benefit from this provision, saving roughly $500 per person annually.
Starting January 1, 2024, eligibility for Medicare’s Low-Income Subsidy expanded, raising the income threshold from 135% to 150% of the federal poverty level. This allows more people to further reduce their costs for insulin and other medications beyond the $35 cap. Several major insulin manufacturers have also voluntarily capped prices at $35 for many patients regardless of insurance status, though these corporate policies can change.